 |
|
Dhivya Sudhan, Ph.D., (left) and Carlos L. Arteaga, M.D. –
Credit UT Southwestern |
“This finding may give clinicians an effective response to neratinib resistance,” Carlos L. Arteaga, M.D., Director of the Simmons Cancer Center at UT Southwestern said in a press release. "That could make a real difference for patients with breast, ovarian, lung, and other cancers harboring HER2 mutations."
Cancers with genetic mutations of the HER2 gene have long been particularly difficult to treat due to the tumor’s ability to eventually overcome and eventually develop resistance to a number of drug treatments. Such tumors have also been showing the same ability to develop resistance to the promising new drug, called neratinib.
In the study published in the journal Cancer Cell, the researchers led by Dhivya Sudan, PhD have shown that HER2 tumor resistance to treatment always occurs when a signaling pathway in the cells is triggered by a gene called TORC1.
Sudan showed that the current cancer drug everolimus blocks the TORC1 pathway, and that combining neratinib and everolimus might prolong the effectiveness of neratinib by preventing resistance. They have shown in laboratory experiments that the combination worked in cell cultures and in mice carrying HER2 mutant tumors.
The next step will be testing this two-drug combination in clinical trials.
In the study published in the journal Cancer Cell, the researchers led by Dhivya Sudan, PhD have shown that HER2 tumor resistance to treatment always occurs when a signaling pathway in the cells is triggered by a gene called TORC1.
Sudan showed that the current cancer drug everolimus blocks the TORC1 pathway, and that combining neratinib and everolimus might prolong the effectiveness of neratinib by preventing resistance. They have shown in laboratory experiments that the combination worked in cell cultures and in mice carrying HER2 mutant tumors.
The next step will be testing this two-drug combination in clinical trials.
No comments:
Post a Comment